Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Reportable Segments
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
The analysis of short-term operating activity ratios reveals a period of fluctuating efficiency, characterized by a general expansion of the cash conversion cycle and a notable increase in the time required to process inventory. While receivable collections remained relatively stable, the company experienced a shift in its inventory management and payables strategies over the observed period.
- Inventory and Receivables Management
- Inventory turnover exhibited a general decline from a high of 2.47 in July 2021 to a low of 1.91 in July 2023, before recovering to 2.14 by April 2026. This downward trend in turnover corresponds with a significant increase in the average inventory processing period, which rose from 148 days to a peak of 191 days in July 2023, indicating a slower movement of goods. In contrast, receivables management remained highly consistent; the receivables turnover ratio fluctuated narrowly between 5.21 and 5.85, and the average collection period stayed within a stable range of 62 to 71 days, suggesting a disciplined and predictable credit collection process.
- Payables and Working Capital Efficiency
- Payables turnover showed a general downward trend, moving from 5.67 in July 2021 to 4.81 in April 2026. This indicates an extension of the average payables payment period, which grew from 64 days to a peak of 91 days in April 2023, before stabilizing between 72 and 79 days. This extension suggests a strategic shift toward utilizing supplier credit to support liquidity. Simultaneously, working capital turnover demonstrated volatility, peaking at 3.84 in July 2022 and ending at 2.77 in April 2026, reflecting varying levels of efficiency in utilizing net current assets to generate revenue.
- Operating and Cash Conversion Cycles
- The operating cycle expanded from 211 days in July 2021 to a peak of 260 days in January 2023, driven primarily by the lengthening inventory processing period. Although the operating cycle contracted to 238 days by April 2026, it remained higher than the baseline. The cash conversion cycle (CCC) followed a similar trajectory, increasing from 147 days to a high of 189 days in January 2024. The expansion of the CCC indicates that more capital was tied up in operations for longer durations, although the impact of slower inventory turnover was partially mitigated by the extended payables payment period.
Turnover Ratios
Average No. Days
Inventory Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | ||||||||||||||||||||||||||
| Inventories | ||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||
| Inventory turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Inventory turnover
= (Cost of products sold, excluding amortization of intangible assetsQ4 2026
+ Cost of products sold, excluding amortization of intangible assetsQ3 2026
+ Cost of products sold, excluding amortization of intangible assetsQ2 2026
+ Cost of products sold, excluding amortization of intangible assetsQ1 2026)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of inventory management efficiency reveals a transition from a high-velocity turnover period to a more stabilized, lower-turnover equilibrium. While both the cost of products sold and total inventory levels exhibited consistent growth over the observed period, the rate of inventory accumulation initially outpaced the growth in sales volume, leading to a reduction in overall turnover efficiency.
- Inventory Turnover Trend
- A distinct downward trend occurred between July 2021 and January 2023, during which the turnover ratio declined from 2.47 to 1.92. This period reflects a decrease in the frequency with which inventory was replaced. Following this decline, the ratio entered a stabilization phase, fluctuating primarily between 1.91 and 2.15 through April 2026.
- Cost of Products Sold Dynamics
- Expenditures associated with the cost of products sold showed a long-term upward trajectory, increasing from 2,598 million USD in July 2021 to 3,398 million USD by April 2026. This represents a significant increase in the volume of goods moving through the system, despite the initial slowing of the turnover ratio.
- Inventory Level Expansion
- Inventory holdings expanded from 4,288 million USD in July 2021 to a peak of 6,309 million USD in January 2026. The growth in inventory assets was more aggressive than the growth in the cost of products sold during the early stages of the period, which accounts for the initial compression of the turnover ratio.
- Operational Equilibrium
- Beginning in January 2024, the inventory turnover ratio demonstrated a recovery and subsequent stabilization, ranging between 1.95 and 2.14. This suggests that inventory management practices were adjusted to better align stock levels with the increased cost of products sold, establishing a consistent operating cadence in the latter half of the period.
Receivables Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Accounts receivable, less allowances and credit losses | ||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||
| Receivables turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Receivables turnover
= (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
÷ Accounts receivable, less allowances and credit losses
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Analysis of receivables turnover indicates a general decline in collection efficiency from July 2021 through April 2026. While net sales experienced overall growth, the rate at which receivables were converted into cash slowed moderately over the analyzed period.
- Receivables Turnover Trends
- The turnover ratio exhibited a period of relative stability between July 2021 and July 2022, maintaining levels between 5.71 and 5.85. A downward shift occurred starting in October 2022, with the ratio decreasing to a low of 5.21 by April 2023. From July 2023 through April 2026, the ratio fluctuated within a lower range, predominantly between 5.15 and 5.58, indicating a persistent decrease in turnover velocity compared to the 2021-2022 baseline.
- Correlation Between Sales and Receivables Growth
- Net sales demonstrated a long-term upward trajectory, rising from 7,987 million in July 2021 to a peak of 9,808 million in April 2026. During the same interval, accounts receivable increased from 5,431 million to 6,643 million. The decline in the turnover ratio suggests that the growth in outstanding receivables has marginally outpaced the growth in net sales, resulting in a slower recovery of credit sales.
- Short-Term Volatility and Stabilization
- Notable volatility is observed in the latter half of the period. A significant dip to 5.15 occurred in April 2025, followed by a recovery to 5.46 in July 2025 and 5.58 in January 2026. This suggests periodic fluctuations in collection cycles or changes in credit terms, although the ratio has remained below the 5.7-5.8 range observed at the start of the analysis period.
Payables Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | ||||||||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||
| Payables turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Payables turnover
= (Cost of products sold, excluding amortization of intangible assetsQ4 2026
+ Cost of products sold, excluding amortization of intangible assetsQ3 2026
+ Cost of products sold, excluding amortization of intangible assetsQ2 2026
+ Cost of products sold, excluding amortization of intangible assetsQ1 2026)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial trajectory of short-term operating obligations shows a general increase in both the volume of product costs and the balance of outstanding accounts payable over the analyzed period. Cost of products sold, excluding amortization of intangible assets, grew from 2,598 million USD in July 2021 to 3,398 million USD by April 2026. Similarly, accounts payable increased from 1,864 million USD to 2,644 million USD over the same timeframe, reflecting an expansion in the scale of operations and associated supplier liabilities.
- Payables Turnover Volatility
- The payables turnover ratio experienced an overall decline during the first half of the period, moving from a peak of 5.67 in July 2021 to a minimum of 4.03 in April 2023. This trend indicates a deceleration in the frequency with which supplier obligations were settled, suggesting an extension of payment cycles or a strategic increase in the use of trade credit.
- Recovery and Stabilization Phase
- A significant recovery in turnover occurred between April 2023 and January 2024, where the ratio rose from 4.03 to 5.60. Following this peak, the ratio entered a phase of relative stabilization. From April 2024 through April 2026, the turnover remained consistent, fluctuating within a narrow range between 4.61 and 5.04, which suggests the establishment of a sustainable payment cadence.
- Correlation Between Payables and Turnover
- A notable inverse correlation is observed in April 2023, where accounts payable reached a localized peak of 2,662 million USD, coinciding with the lowest recorded turnover ratio of 4.03. This suggests that the decline in turnover was driven by a temporary accumulation of payables. As accounts payable were managed and subsequently grew in alignment with the cost of products sold, the turnover ratio normalized.
Working Capital Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||||
| Less: Current liabilities | ||||||||||||||||||||||||||
| Working capital | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||
| Working capital turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Working capital turnover
= (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of the short-term operating activity reveals a period of significant volatility in working capital management, resulting in fluctuating efficiency levels in generating net sales. While net sales exhibited a general upward trajectory over the observed period, the working capital turnover ratio was heavily influenced by sharp contractions and expansions in the working capital base.
- Working Capital Turnover Trends
- The turnover ratio began at 2.15 in July 2021 and reached a peak of 3.84 by July 2022. This peak represents the highest point of efficiency in the dataset, although it coincided with a substantial reduction in working capital. Following this spike, the ratio stabilized, generally fluctuating between 2.40 and 3.22. By April 2026, the ratio stood at 2.77, indicating a higher baseline of operational efficiency compared to the 2021 period.
- Net Sales Growth
- Net sales demonstrated a consistent long-term increase. Starting at 7,987 million USD in July 2021, sales reached a peak of 9,808 million USD by April 2026. This growth suggests a strengthening market position or increased demand, which provided a supportive foundation for the turnover ratios despite the fluctuations in available working capital.
- Working Capital Volatility
- Working capital experienced significant shifts, dropping from 14,670 million USD in July 2021 to a low of 8,086 million USD in July 2022. This reduction was the primary driver for the surge in the turnover ratio during that period. Subsequently, working capital recovered and fluctuated, ending at 13,129 million USD in April 2026. The inverse relationship between the working capital volume and the turnover ratio is evident, particularly during the 2022 contraction.
- Operational Efficiency Insights
- The data indicates a transition in how short-term assets are utilized to generate revenue. The shift from a turnover ratio of approximately 2.1x in 2021 to a range of 2.4x to 3.2x in later periods suggests that the organization has become more efficient at utilizing its operating liquidity to drive sales growth. The most recent figures show a stabilization of this efficiency, balancing increased sales with a moderately higher working capital requirement.
Average Inventory Processing Period
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||
| Inventory turnover | ||||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||
| Average inventory processing period1 | ||||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The inventory management metrics exhibit two distinct phases: an initial period of declining operational efficiency followed by a phase of relative stabilization characterized by moderate fluctuations.
- Inventory Turnover Ratio
- A consistent downward trend is observed from July 2021 to January 2023, where the ratio declined from 2.47 to 1.92. Following this period, the ratio entered a stabilization phase, fluctuating within a tighter range between 1.91 and 2.15. The most recent observation in April 2026 shows a recovery to 2.14, indicating an improvement in the frequency of inventory replacement compared to the 2023 lows.
- Average Inventory Processing Period
- The processing period mirrored the turnover decline with a steady increase in the number of days required to move inventory. The period rose from 148 days in July 2021 to a peak of 191 days in July 2023. After this peak, the processing period fluctuated between 170 and 187 days. The final reading of 171 days in April 2026 suggests a reduction in the duration inventory is held relative to the peak levels seen in 2023.
- Operational Correlation and Liquidity
- A direct inverse correlation exists between the turnover ratio and the processing period. The expansion of the processing period through 2022 and early 2023 indicates a slowdown in inventory conversion, which typically suggests higher holding costs or a shift in supply chain strategy. The subsequent stabilization and the recent decrease to 171 days suggest a normalization of inventory velocity and a marginal improvement in short-term asset liquidity.
Average Receivable Collection Period
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||
| Receivables turnover | ||||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||
| Average receivable collection period1 | ||||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals an inverse relationship between the receivables turnover ratio and the average receivable collection period. The metrics indicate a period of initial stability, followed by a moderate decline in collection efficiency, and a subsequent phase of stabilization.
- Receivables Turnover Trends
- The turnover ratio maintained a consistent range between 5.71 and 5.85 from July 2021 through July 2022. Starting in October 2022, a downward trend emerged, with the ratio descending to a low of 5.15 by January 2025. In the final quarters of the period, the ratio showed a slight recovery, stabilizing between 5.44 and 5.58.
- Average Receivable Collection Period Analysis
- The collection period was characterized by high stability in the first year, fluctuating minimally between 62 and 64 days. A notable increase occurred beginning in October 2022, with the period extending to 70 days by January 2023. This elevated trend persisted through early 2025, reaching a peak of 71 days. The most recent observations from July 2025 through April 2026 show a reduction in the collection cycle, returning to a range of 65 to 67 days.
- Operating Efficiency Insights
- The expansion of the collection period by approximately one week between 2021 and early 2025 indicates a temporary decrease in the velocity of cash inflows from credit sales. This suggests either a broadening of credit terms offered to customers or a decrease in the efficacy of collection processes during that window. The recent trend toward 65 days suggests a normalization of credit management and a marginal improvement in liquidity conversion.
Operating Cycle
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||
| Operating cycle1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibits a period of expansion followed by a phase of relative stabilization, characterized primarily by fluctuations in inventory management rather than credit collection efficiency.
- Average Inventory Processing Period
- A consistent upward trend is observed from July 2021, where the period stood at 148 days, peaking at 190 days by January 2023. Following this peak, the processing period entered a period of volatility, fluctuating between a low of 170 days in April 2024 and a high of 191 days in July 2023. The period concluded at 171 days in April 2026, indicating a partial reversal of the initial inventory buildup.
- Average Receivable Collection Period
- The collection period remained remarkably stable throughout the entire analyzed timeframe. Values fluctuated within a narrow range of 62 to 71 days, with the majority of quarters maintaining a collection period between 67 and 70 days. This stability suggests a consistent and disciplined approach to credit management and receivables recovery.
- Operating Cycle Dynamics
- The total operating cycle mirrors the trajectory of the inventory processing period, as the receivable collection period provided a constant baseline. The cycle lengthened from 211 days in July 2021 to a maximum of 260 days in January 2023. Subsequent performance shows a stabilization phase where the cycle generally oscillated between 238 and 258 days. The final recorded value of 238 days represents a contraction from the 2023 peak, driven by the reduction in inventory holding times.
Overall, the data indicates that the duration of the operating cycle is heavily sensitive to inventory turnover rates. While receivable collection is managed with high consistency, the variability in the total cycle is almost entirely attributable to changes in the time required to process and sell inventory.
Average Payables Payment Period
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||
| Payables turnover | ||||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||
| Average payables payment period1 | ||||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The management of accounts payable reflects a period of volatility between 2021 and 2024, followed by a phase of relative stabilization. The operational cycle witnessed a notable extension in the time taken to settle obligations with suppliers, peaking in early 2023 before correcting toward a historical mean.
- Payables Turnover Dynamics
- The payables turnover ratio experienced a gradual decline from 5.67 in July 2021 to a low of 4.03 in April 2023. This decline indicates a slower rate of payment to creditors during this window. A subsequent recovery occurred, with the ratio peaking at 5.60 in January 2024, before stabilizing within a narrow range between 4.64 and 5.04 through April 2026.
- Average Payables Payment Period Trends
- The average payment period began at 64 days in July 2021 and trended upward to a maximum of 91 days by April 2023. This expansion represents a significant increase in the duration of short-term credit utilized from suppliers. Following this peak, a sharp reduction was observed, with the period falling to 65 days by January 2024. For the remainder of the observed timeline, the payment period remained consistent, fluctuating between 72 and 79 days.
- Correlation and Operational Stability
- An inverse correlation between the turnover ratio and the payment period is maintained throughout the duration of the analysis. The transition from a peak payment period of 91 days back to a stabilized average of approximately 76 days suggests a normalization of working capital management strategies. The absence of significant volatility from 2024 through 2026 indicates a consistent approach to supplier credit terms and cash flow planning.
Cash Conversion Cycle
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||||
| Average payables payment period | ||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||
| Cash conversion cycle1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The operational efficiency regarding working capital management exhibits a general expansion of the cash conversion cycle over the analyzed period. Starting at 147 days in July 2021, the cycle reached a peak of 189 days by January 2024, reflecting a prolonged period of capital tie-up before stabilizing between 162 and 175 days in the final observation quarters.
- Average Inventory Processing Period
- A sustained upward trend is observed from July 2021, where the period stood at 148 days, peaking at 191 days in July 2023. This indicates a significant slowdown in inventory turnover during this interval. Following the peak, the period experienced moderate volatility, eventually declining to 171 days by April 2026. This metric serves as the primary driver of the overall variance in the cash conversion cycle.
- Average Receivable Collection Period
- The collection of receivables remained remarkably stable throughout the entire period, with values fluctuating narrowly between 62 and 71 days. This consistency suggests a highly disciplined credit management policy and predictable payment patterns from clients, contributing negligible volatility to the operating cycle.
- Average Payables Payment Period
- The duration for settling supplier obligations increased from 64 days in July 2021 to a peak of 91 days in April 2023. After this peak, the period normalized and stabilized within a range of 72 to 79 days. The strategic extension of payables during the mid-period provided a partial offset to the increasing inventory holding times, thereby mitigating some of the pressure on the cash conversion cycle.
- Cash Conversion Cycle Synthesis
- The overall cash conversion cycle was dominated by the fluctuations in inventory processing. While the increase in the payables payment period acted as a liquidity buffer, it was insufficient to fully neutralize the impact of slower inventory turnover. The subsequent contraction of the cycle toward 162 days by April 2026 indicates a gradual recovery in operational liquidity and improved asset turnover efficiency.